Schrödinger, Inc. (Nasdaq: SDGR) today announced that new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, and SGR-4174, its SOS1 inhibitor, will be presented at the American ...
Expanding the therapeutic index of ADCs Synaffix’s site-specific–conjugation and payload-enhancement technologies are improving the safety and efficacy of antibody-drug conjugates (ADCs ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback